Telix Pharmaceuticals

Develops targeted radiation diagnostics and therapies

Telix Pharmaceuticals

Develops targeted radiation diagnostics and therapies

Overview

Telix Pharmaceuticals develops and commercializes diagnostic and therapeutic products that use targeted radiation to diagnose and treat cancer and rare diseases. Its pipeline covers urologic oncology (prostate and kidney cancers), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. The treatments work by delivering targeted radiation to diseased tissues, enabling more precise decisions for treatment and allowing for personalized therapy. The company differentiates itself through a global, robust supply chain and a focus on integrating diagnostic and therapeutic options to address unmet medical needs, along with strong commitments to patient care, ethical practices, and environmental responsibility. Telix’s goal is to improve quality of life and outcomes for patients by providing targeted, clinically meaningful diagnostic and therapeutic solutions that support better treatment decisions and personalized care.

Significant Headcount Growth

Work here?Claim your company

About Telix Pharmaceuticals

Simplify's Rating

Why Telix Pharmaceuticals is rated

B-

Rated B on Competitive Edge

Rated B on Growth Potential

Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Melbourne, Australia

Founded

2015

Get referred to Telix Pharmaceuticals

See people who can refer or advise you

Simplify's Take

What believers are saying

FDA approved Pixclara on September 13, 2026, opening Telix's first brain-cancer imaging market.
H1 2026 revenue reached $477 million, up 22%, with EBITDA rising 146%.
BiPASS enrolled 350 patients and Telix aligned with FDA on a U.S. NDA pathway.

What critics are saying

Telix still depends on FDA manufacturing acceptance for Zircaix resubmission in 2026.
The $2.35 billion ITM deal brings dilution, debt, and integration strain through 2027.
Novartis, with Lutathera and Pluvicto, attacks Telix in GEP-NETs and prostate therapy.

What makes Telix Pharmaceuticals unique

Telix sells both diagnostics and therapies across the same radiopharmaceutical platform.
Illuccix and Gozellix give Telix a commercial prostate imaging franchise in 24 countries.
ITM adds isotope manufacturing, distribution, and lutetium-177 supply across more than 65 countries.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1.2B

Above

Industry Average

Funded Over

7 Rounds

Post IPO Convertible funding comparison data is currently unavailable. We're working to provide this information soon!

Post IPO Convertible Funding Comparison Coming Soon

Benefits

Annual Performance Bonus
Equity-Based Incentive Program
Paid Vacation
Paid Wellness Days
Hybrid Work Options
Remote Work Options

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

16%

2 year growth

Daily Dispatch

Oct 20th, 2026

Philadelphia cyclotron to give Telix a dedicated source of rare alpha isotope.

Philadelphia cyclotron to give Telix a dedicated source of rare alpha isotope. Telix has partnered with a new Franco-Belgian venture to produce astatine-211 in the United States. The isotope is scarce but is being studied closely as a new way to deliver radiation straight to cancer cells. The collaboration is with Ekalia, a joint venture between Belgian cyclotron maker IBA and French nuclear group Framatome. The first of IBA's alpha-beam cyclotrons will be installed and run at Telix's RLS Radiopharmacies site in Trevose, near Philadelphia. Astatine-211 is an alpha-emitting radioisotope under investigation for targeted alpha therapy. In this approach, a drug carries a radioactive payload directly to a tumour. The partners describe the isotope as promising for new cancer treatments, but say limited production capacity has held back wider use. Their answer is a network of production sites close to the clinical centres that need the isotope. Ekalia chief executive Bruno Scutnaire said the technology was designed to put production where it is needed. "IBA's specialised alpha-beam cyclotron technology is designed to enable reliable astatine-211 production at the point of need. Building on our work with Framatome in Europe, Telix's U.S. infrastructure enables us to move faster towards establishing our first U.S. production unit, while laying the foundations for Ekalia's broader development in the country." The deal brings the IBA-Framatome partnership, set up in Europe to produce astatine-211 at industrial scale, into the US. Each company brings something different. IBA supplies the cyclotron technology and Framatome its nuclear and isotope production expertise. Telix contributes its US radiopharmacy network and "last-mile" distribution, along with its clinical portfolio and drug development capability.

Yahoo Finance

Oct 19th, 2026

Telix and Ekalia team up to produce astatine-211 in the US for cancer therapy

Telix Pharmaceuticals and Ekalia, a joint venture between IBA and Framatome, will collaborate on US production of astatine-211, an alpha-emitting isotope being studied for targeted alpha therapy. They announced the deal on October 19, 2026. The first IBA alpha-beam cyclotron will be installed at Telix's RLS Radiopharmacies site in Trevose, near Philadelphia. The parties may add more RLS sites as demand grows. The deal gives Telix long-term, priority access to the isotope for its alpha therapy pipeline, including TLX102-Tx, a candidate for glioblastoma and leptomeningeal disease. It will also supply third-party academic and industry programmes. Astatine-211 is promising, but limited production capacity has held back wider use.

Yahoo Finance

Oct 18th, 2026

Three Australian growth stocks with insider backing: PDI Gold, Telix and Codan

Simply Wall St has picked three Australian growth stocks with high insider ownership: PDI Gold, Telix Pharmaceuticals, and Codan. The screen favours fast growers that can handle higher costs as US inflation keeps interest rate risks in focus. PDI Gold (market cap A$4.3 billion) runs the Kiniéro Gold Mine in Guinea. Its reliance on oxide ore could lift costs and squeeze margins once that phase ends. Telix Pharmaceuticals (A$5.3 billion) develops radiopharmaceutical imaging agents and cancer therapies. Its imaging products brought in $803.8 million (USD) in the 2025 financial year, and growth hinges on its late-stage pipeline. Codan (A$11.4 billion) makes radio communications systems and metal detectors. Rising defence spending and demand for unmanned systems are expanding its order book.

Anderson Publishing, Ltd.

Oct 14th, 2026

Telix to present 20 abstracts at EANM 2026 Congress.

Telix to present 20 abstracts at EANM 2026 Congress. October 14, 2026 · News Release Telix has announced that it will be presenting 20 company-related abstracts at the forthcoming 39th Annual Congress of the European Association of Nuclear Medicine (EANM) scheduled for October 17-21, 2026, in Vienna, Austria. Dr. David N. Cade, Chief Medical Officer of Telix, emphasized that the company's robust presence at the event showcases the extensive development of its pipeline, which includes important therapeutic studies, precision diagnostics, and advanced technologies. He noted that the inclusion of 12 abstracts in top-rated oral presentations is a significant acknowledgment of the quality and clinical relevance of Telix's research. A symposium focusing on the future of theranostics in urologic oncology is also planned. Key presentations will feature pivotal trials such as the Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma, the Phase 3 LUTEON trial of TLX250-Tx in clear cell renal cell carcinoma (ccRCC), and interim results from the PTherpan-Lu trial of TLX597-Tx in metastatic androgen pathway modulation-resistant prostate cancer (mAPMR). The event will also highlight topline Phase 3 data for TLX591-Px (Illuccix) PET imaging in prostate cancer among Chinese men, as well as real-world applications of TLX250-Px (Zircaix) in ccRCC. Additionally, Telix will sponsor the EANM Sanjiv Sam Gambhir Young Investigator Award to honor the legacy of the esteemed educator. Attendees can visit booth #527 to learn more about collaboration opportunities involving Illuccix(R), the PSMA-PET imaging agent, along with contributions from Telix's theranostic pipeline and innovative medical technologies, including the SENSEI(R) miniature drop-in gamma probe and QDOSE(R) dosimetry software. Sponsored symposium details. Title: The future doesn't wait: The next era of theranostics in urologic oncology. Date & Time: 18-Oct-26, 13:15 - 14:45 Location: Hall F2, Austria Center Vienna Chair: J. Calais, Gustave Roussy, IGR and Université Paris-Saclay, Paris, France * The theranostic revolution * The evolving role of PSMA-PET in prostate cancer * Next-generation PSMA therapeutics: Overcoming today's challenges * Panel discussion * Extending prostate cancer theranostic success to broader GU diseases Selected oral presentations. * ELEGANCE: Prospective pilot study assessing imaging performance of TLX250-Px in patients with hepatocellular carcinoma, biliary tract cancer or gastro-enteropancreatic neuroendocrine neoplasms. * * Date and Time: 18-Oct-26, 08:00 - 09:30 * Presenter: Clement Bailly * HIMIKO: TLX591-Px PET/CT in hepatocellular carcinoma. * * Date and Time: 18-Oct-26, 08:00 - 09:30 * Presenter: Rachel Bardy * Exploring carbonic anhydrase IX as a diagnostic imaging target using TLX250-Px in Von Hippel-Lindau Disease. * * Date and Time: 18-Oct-26, 15:00 - 16:30 * Presenter: Fabrizia Gelardi * LUTEON: Phase 3 study assessing safety and efficacy of TLX250-Tx in advanced ccRCC. * * Date and Time: 18-Oct-26, 15:00 - 16:30 * Presenter: Ghoufrane Tlili * Building the traceability backbone for radiopharmaceutical therapy: First results from the PDIB Secondary Standards Laboratory Network. * * Date and Time: 19-Oct-26, 08:00 - 09:30 * Presenter: Steven Graves With the exception of Illuccix, all products mentioned are investigational and have not received marketing authorization in any jurisdiction. More in theranostics. October 15, 2026 October 6, 2026

Australian Associated Press

Oct 14th, 2026

Telix highlights pivotal trials in prostate, brain and renal cancers and next generation theranostics at EANM.

Telix highlights pivotal trials in prostate, brain and renal cancers and next generation theranostics at EANM. medical research October 14, 2026 MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna, Austria from October 17-21, 2026. Dr. David N. Cade, Telix Group Chief Medical Officer, said, "Our expansive presence at EANM reflects the breadth and maturity of Telix's pipeline, spanning pivotal therapeutic studies, precision diagnostics and next-generation technologies. The selection of 12 abstracts for top-rated oral presentations is a strong recognition of the quality and clinical relevance of this work. We look forward to continuing this discussion at our sponsored symposium on the future of theranostics in urologic oncology." Key presentations include the Phase 3 IPAX BrIGHT trial of TLX101-Tx in recurrent glioblastoma, the Phase 3 LUTEON trial of TLX250-Tx in ccRCC, and interim results from the PTherpan-Lu trial of TLX597-Tx in mAPMR prostate cancer[[1]]. Topline Phase 3 data for TLX591-Px (Illuccix) PET[[2]] imaging of prostate cancer in Chinese men will also be presented, together with real-world experience with TLX250-Px (Zircaix[[3]]) in ccRCC, and research from its targeted alpha therapy and MedTech programs. As in previous years, Telix will support the EANM Sanjiv Sam Gambhir Young Investigator Award, in memory of an extraordinary man and inspiring educator.

Recently Posted Jobs